Bringing CNS Members Together to Make Children’s Lives Better



CNS Research Committee

Daniel Calame, MD, PhD
Baylor College of Medicine


Dr. Clardy will discuss the ExTINGUISH Trial, a randomized controlled trial of Inebilizumab for anti-NMDAR Encephalitis, framed in the context of learning about the NIH NeuroNEXT Clinical Trial Network, and the challenges of studying rare neurologic diseases. The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) is an NINDS program which seeks to increase efficiency of clinical trials in neurology by providing a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in adult and pediatric neurological disorders.

About the Speakers

Stacey Clardy, MD, PhD

Stacey Clardy is the principal investigator (PI) of an NIH U01 grant (via the NeuroNEXT Clinical Trials Network) to fund the ExTINGUISH Trial – the first NIH-funded, prospective, international, randomized clinical trial for NMDA receptor encephalitis, at 25 US sites and 2 European sites, with enrollment currently ongoing. She established the Autoimmune Neurology Clinic at the University of Utah ten years ago – one of the few clinics in the United States focused on serving this group of patients. Dr. Clardy is also the director of the Autoimmune Neurology Fellowship program, and the editor of the Neurology Podcast for the journal Neurology and the Neurology Minute for the American Academy of Neurology.